Tropical Journal of Pharmaceutical Research

Original Research Article | OPEN ACCESS

Effect of combination of glucocorticoid and different doses of atorvastatin on neural function, blood lipid levels and magnetic resonance imaging in patients with multiple sclerosis

Qinli Zhang¹, Hong Liu¹ , Bowen Liu², Qingqing Zhu²

¹Department of Neurology, Heping Hospital Affiliated to Changzhi Medical College, Changzhi City, Shanxi Province, China; ²Changzhi Medical College, 046000, Changzhi City, Shanxi Province, China.

For correspondence:- Hong Liu Email: Liuhongdr@outlook.com

Accepted: 02 August 2022 Published: 29 August 2022

Citation: Zhang Q, Liu H, Liu B, Zhu Q. Effect of combination of glucocorticoid and different doses of atorvastatin on neural function, blood lipid levels and magnetic resonance imaging in patients with multiple sclerosis. Trop J Pharm Res 2022; 21(8):1786-1792 doi: 10.4314/tjpr.v21i8.28

© 2022 The authors.
This is an Open Access article that uses a funding model which does not charge readers or their institutions for access and distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0) and the Budapest Open Access Initiative (http://www.budapestopenaccessinitiative.org/read), which permit unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited..

Abstract

Purpose: To determine the efficacy of the combination of glucocorticoid and different doses of atorvastatin in the treatment of patients with multiple sclerosis (MS).

Methods: Sixty MS patients treated at Heping Hospital Affiliated to Changzhi Medical College from January 2020 to June 2021, were equally and randomly assigned to study group (OG) and control group (CG). Patients in OG were treated with glucocorticoid and atorvastatin (half in low-dose, LDG; 20 mg/day) and the other half, in high-dose atorvastatin (HDG, 40 mg/day)). Patients in CG were treated with glucocorticoid and placebo. Changes in magnetic resonance imaging (MRI), blood lipids, RhoA, and neural function were determined.

Results: After treatment, Expanded Disability Status Scale (EDSS) score was lower in HDG than in LDG and CG (p < 0.05). Total cholesterol (TC), low density lipoprotein cholesterol (LDL-C), triglycerides (TG) and lipoprotein a (LP(a)) were significantly reduced and followed the rank order: HDG < LDG < CG (p < 0.05). No appreciable differences occurred in HDL-C levels amongst HDG, LDG and CG (p > 0.05). Furthermore, RhoA levels were lower in HDG than in LDG and CG, with lower levels in LDG than in CG (p < 0.05). There were lower numbers of T2 lesions in HDG than in LDG and CG at 28 days, 3, 6 and 12 months, post-treatment (p < 0.05).

Conclusion: Glucocorticoid and high-dose atorvastatin combination is better at reducing neurological dysfunction and improving blood lipid indicators in MS patients. This finding may provide a useful guide in the determination of the optimal dose of atorvastatin.

Keywords: Atorvastatin, Glucocorticoid, Multiple sclerosis (MS), MRI performance